Here are six key points:
1. The Triojection System is designed for treating disc herniations with an intradiscal injection of ozone gas.
2. The study will include a total of 50 patients, which Minimus expects to meet by September 2017.
3. Minimus hopes to gather primary endpoint data by the end of the first quarter in 2018.
4. Researchers are measuring improvement in leg pain, back pain and disability, among other outcomes, at six months following treatment.
5. Minimus has clinical sites in Italy, Switzerland and Greece.
6. The Triojection System is already CE marked.
More articles on devices:
Filling a biologic void — Pinnacle Spine’s CEO Zach Sowell on the pioneering bone graft technology
FDA approves full-body MRI for St. Jude Medical’s Proclaim Elite SCS System: 5 key points
1st cases performed with Xtant Medical’s Xspan Laminoplasty Fixation System: 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
